Pacific Edge Appoints Danielle Gutter VP Sales, PEDUSA

Pacific Edge today announces the appointment of Danielle Gutter as its new Vice President of Sales, PEDUSA.

Ms Gutter joined Pacific Edge Diagnostics USA (PEDUSA) on April 10th, 2023 and will head up Pacific Edge’s sales efforts for Cxbladder in the USA, leading the three regional sales teams, the virtual sales team, the national accounts team, and sales operations.

Ms Gutter brings a track record in driving growth in senior sales leadership positions across the biotechnology sector. Most recently she was Vice President of Global Sales at digital healthcare company Igentify, where she was charged with building global sales strategy, marketing, and promoting the company’s first-to-market digital genetic counselling platform.

Prior to that Ms Gutter held sales leadership roles in the oncology diagnostics division at Natera, diagnostics company Centogene, and scientific equipment and services provider Thermo Fisher Scientific. At Natera she built, launched, and led Oncology Division sales teams focused on the Signatera test for circulating tumor DNA (ctDNA) and immunotherapy products and testing. At Centogene she re-built and launched the company’s US sales team and grew its market share.

Pacific Edge Chief Executive Dr Peter Meintjes said: “We are delighted Danielle is joining the company. She brings to Pacific Edge a strong track record in sales, diagnostics, and oncology, alongside sales operations and management. She also has proven skills in collaborating with other commercial teams to deliver strategic success. We are looking forward to her joining the team.”

Ms Gutter said: “The suite of Cxbladder tests represent a compelling value proposition for patient management in oncology by detecting the signs of cancer early. The tests are non-invasive, which enhances patient compliance during diagnostic workup and surveillance for cancer recurrence, leading to improvements in patient health outcomes.

“Cxbladder offers opportunities for clinicians to safely de-intensify urological workups, saving healthcare providers and payors time and money, while allowing them to focus resources on patients that require care.

“Of course, it is imperative that these real world benefits are supported by robust clinical evidence and it is exciting to join a company that is so committed to developing clinical evidence for commercial coverage. I am looking forward to working with Peter and the broader team, as we build on the company’s growing commercial success.”

Ms Gutter holds a BSc (Hons) from Widener University.

An image of Ms Gutter can be downloaded from the following link.